Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 172.41 1.29% 2.19
VRTX closed up 1.29 percent on Friday, October 11, 2019, on 81 percent of normal volume.

Earnings due: Oct 22

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical VRTX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Gapped Up Strength 0.00%
Multiple of Ten Bullish Other 1.29%
Multiple of Ten Bearish Other 2.18%
Down 3 Days in a Row Weakness 2.18%
Multiple of Ten Bearish Other 1.69%
20 DMA Resistance Bearish 0.10%
MACD Bullish Signal Line Cross Bullish 0.10%
Multiple of Ten Bullish Other 0.10%
20 DMA Resistance Bearish -0.01%

Older signals for VRTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Chemistry Chemical Compounds Organic Compounds Infection Influenza Cystic Fibrosis Serious Diseases Cyclopropanes Autoimmune Disease Breakthrough Therapy Hepatitis C Virus Organofluorides Treatment Of Cystic Fibrosis HCV Infection
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 195.81
52 Week Low 151.8
Average Volume 1,066,201
200-Day Moving Average 178.1123
50-Day Moving Average 176.4132
20-Day Moving Average 171.9145
10-Day Moving Average 169.977
Average True Range 4.0952
ADX 28.03
+DI 20.2165
-DI 24.1379
Chandelier Exit (Long, 3 ATRs ) 167.2644
Chandelier Exit (Short, 3 ATRs ) 177.5156
Upper Bollinger Band 178.7487
Lower Bollinger Band 165.0803
Percent B (%b) 0.54
BandWidth 7.950696
MACD Line -1.6114
MACD Signal Line -1.9202
MACD Histogram 0.3088
Fundamentals Value
Market Cap 43.47 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 165.78
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 177.80
Resistance 3 (R3) 177.97 176.34 176.90
Resistance 2 (R2) 176.34 174.97 176.26 176.60
Resistance 1 (R1) 174.38 174.12 175.36 174.21 176.30
Pivot Point 172.75 172.75 173.25 172.67 172.75
Support 1 (S1) 170.79 171.38 171.77 170.62 168.52
Support 2 (S2) 169.16 170.53 169.08 168.22
Support 3 (S3) 167.20 169.16 167.92
Support 4 (S4) 167.03